BioXcel Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for BioXcel Therapeutics, Inc. (BTAI) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-59.60-179.05-165.76-106.93-82.17-32.97-19.27
Depreciation & Amortization0.311.980.330.300.190.160.02
Stock Based Compensation6.1618.6117.3419.4614.610.000.00
Change in Working Capital0.822.3410.404.980.902.572.66
Change in Accounts Receivable-0.060.18-0.250.000.000.000.00
Change in Inventory1.31-0.01-1.990.000.000.000.00
Change in Accounts Payable-4.33-3.2213.034.853.200.000.00
Change in Other Working Capital3.903.531.940.13-2.180.000.00
Other Operating Activities-20.1820.171.9419.4814.743.140.00
Net Cash from Operating Activities-72.03-155.01-135.34-82.15-66.35-27.10-13.51
Investing Activities
Capital Expenditures0.000.02-0.14-0.450.320.87-0.34
Net Cash from Investing Activities0.00-0.02-0.14-0.45-0.32-0.87-0.34
Financing Activities
Debt Repayment-2.50-0.18-2.650.000.000.000.00
Common Stock Issued39.6927.030.28102.45255.7917.8156.51
Common Stock Repurchased-0.05-0.030.000.00-9.020.000.00
Other Financing Activities-0.47-1.02-2.650.00-17.820.02-0.56
Net Cash from Financing Activities36.6626.5296.24102.45247.3617.8355.53
Summary
Net Change in Cash-35.37-128.50-39.2419.85180.69-10.1441.68
Cash at Beginning of Period65.22193.73232.97213.1232.4342.570.89
Cash at End of Period29.85-155.03193.73232.97213.1232.4342.57
Free Cash Flow-72.03-155.03-135.48-82.60-66.67-27.97-13.85
Supplemental Disclosures
Interest Paid7.977.552.700.040.030.060.00